Krukemeyer MG* and Wagner W
Department of Radio-Oncology, Paracelsus-Hospital, Sedanstr. 109 D-49076 Osnabrück, Germany
Received Date: February 22, 2013; Accepted Date: February 26, 2013; Published Date: February 28, 2013
Citation: Krukemeyer MG, Wagner W (2013) Nanomedicine in Cancer Treatment. J Nanomed Nanotechol 4:166. doi:10.4172/2157-7439.1000166
Copyright: ©2013 Krukemeyer MG, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Visit for more related articles at Journal of Nanomedicine & Nanotechnology
More than half of the populations over 65 years old suffer from a cancer disease. Tumor research, therefore, also seeks new and more efficient forms of therapy.
Since cytostatics have harmful effect on all cells in the human body, the concept of magnetic drug targeting offers an interesting alternative to conventional tumor therapy . The concept has been described in the literature and tested on animal models. The intravasal availability of the ferrofluids and the magnetic sensitivity were critical. The particles must be large enough to be attracted by a magnetic field, and to migrate into the tumor in this way, in order to release their active substance there .
A magnetic field strength of 0.6 tesla was applied externally to the body . Iron oxides [Fe3O4] were administered intravasally into a vein or artery (Figure 1). Cytostatics were bonded to the iron oxides [Fe3O4]. The animal studies were conducted with sarcomas such as rhabdomyosarcoma (Tables 1 and 2).
|Group||Operative measure||Duration*||Number of animals|
|I||1 mg/kg BW MagnaDrug mitoxantrone** in a magnetic field||Once on one day 30 min||6|
|II||1 mg/kg BW MagnaDrug mitoxantrone** without a magnet||30 min||6|
|III||1mg/kgBW mitoxantrone** without a magnetic field||30 min||6|
|IV||1 mg/kg BW MagnaDrug mitoxantrone**||1st day 30 min
2nd day 30 min
|V||1 mg/kg BW MagnaDrug mitoxantrone** without a magnet||1st day 30 min||6|
|VI||1mg/kg BW mitoxantrone** without a magnetic field||1st day 30 min||6|
*Duration: Duration of exposure to the magnetic field
** Slow intravenous injection over 5 minutes
Total number=Σ 36
Table 1: Study groups in the biodistribution.
|General condition||survival, reflex status, weight|
|Biodistribution of iron||blood, tumor, liver|
Table 2: Target values and parameters investigated.
Results: It was demonstrated that mitoxantrone has a higher concentration in the tumor than the mitoxantrone concentration , in the peripheral blood (Table 3).
|Group I||Group II||Group III||Group IV||Group V|
* Significant p values
** Highly significant p values
Table 3: p values for comparison of the mitoxantrone concentration in the tumor between Groups I - VI.
The results revealed that iron bonded cytostatics contributed towards a reduction in the volume of the tumor and encouraged for further experimental surgical studies (Table 4).
|Patient L.K.||Unit||Day ‑2||Day 0||Day 1||Day 2||Day 3||Day 4||After 2 weeks|
Table 4: Iron oxide and ferritin on day -2, 0, 1, 2, 3 and 4 and after 2 weeks.
70-year old female patient with metastases mammary carcinoma on left, initial diagnosis in May 2008, has been detected. Further diagnosis was arterial hypertension and obesity (97 kg, 161 cm).
Results: The CT showed an exulcerated timorous mass approx. 10 cm in diameter in the region of the left breast (500 ml), Table 5 shows the pathologically changed axillary lymph nodes of maximum 2.5 cm diameter and multiple metastases of maximum 5 cm diameter, in both lobes of the liver (Figure 2).
|Sample designation||Sample 1||Sample 2|
|Matrix||blood||tumor tissue directly under the magnet|
|Microwave pressure break-down HNO3/H2O2||X||X|
|Iron, tot. (Fe)||µg/dl||151||440|
Table 5: Blood sampling on the 4th day.
The volume of the smaller liver metastasis, identified with an arrow in the right lobe, has decreased from approx. 14.9 cm3 to approx. 8.0 cm3, i.e. by approx. 45% and until 25.03.2009 to 90% (Figure 3).
The exulceration at the breast stopped, so that an imputation of the breast had been successfully performed in 11/2008. The patient has responded well to the therapy. Her physical and mental condition is good and well tolerated, she felt well, and no complications or side effects occurred in the patient.
The animal study shows in the living organism, an effect of the magnetic field, concentrating on the iron particles. The case study on a human shows a reversible granulocytopenia, neither gastritis, nor alopecia or stomatitis. The data show partial metastatic reduction as per literature. Further patients were treated with the same dose; longterm results are being investigated. This therapy method is a possible option with relatively few side effects.